Physician

Alexander Philipovskiy, M.D., PH.D

According to 2025 Medicare claims, Alexander Philipovskiy, M.D., PH.D (NPI: 1598074544) practices medical oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32746-2115. Philipovskiy is affiliated with the Texoma Clinical Partners ACO, LLC (ACO ID: A4585), participating under the MSSP model.

Philipovskiy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 210 traditional Medicare patients, billed 31,097 HCPCS/CPT codes, and received $169,023 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 276 prescription claims across 44 beneficiaries totaling $89,402 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 144 records totaling $330,700. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $8,678 to $169,023. In contrast, Part D prescription costs have fallen sharply in recent years, from $272,168 to $89,402. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	67	131	$8,678
2018	78	130	$7,360
2019	65	120	$8,065
2020	63	147	$10,607
2021	103	209	$15,384
2022	74	4,053	$22,411
2023	116	16,698	$160,215
2024	210	31,097	$169,023

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	85	391	$272,168
2018	110	415	$397,443
2019	115	583	$704,273
2020	131	679	$1,112,780
2021	154	555	$1,138,687
2022	70	240	$382,310
2023	24	199	$118,191
2024	44	276	$89,402

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	60	146	$98
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	59	147	$13
96372	Injection of drug or substance under skin or into muscle	42	71	$10
36415	Insertion of needle into vein for collection of blood sample	156	670	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	136	392	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	19	575	$10,718
Prochlorperazine Maleate	Prochlorperazine Maleate	13	270	$357
Prednisone	Prednisone	19	274	$135
Pregabalin	Pregabalin	11	300	$96

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	90	$2,651	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	54	$328,049	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexander Philipovskiy, M.D., PH.D?

Tedicare shows public-source Medicare data for Alexander Philipovskiy, M.D., PH.D (NPI 1598074544), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander Philipovskiy, M.D., PH.D have ACO affiliation data?

Alexander Philipovskiy, M.D., PH.D is shown with ACO affiliation data for Texoma Clinical Partners ACO, LLC (MSSP, ACO ID A4585).

What billing organization is linked to Alexander Philipovskiy, M.D., PH.D?

Alexander Philipovskiy, M.D., PH.D is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Alexander Philipovskiy, M.D., PH.D have Open Payments data?

Alexander Philipovskiy, M.D., PH.D has 144 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.